BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
PR Newswire•18/08/2026•08:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.